Kidney Compass: FIND-CKD Finerenone Data in FSGS and Treatment Sequencing

Researchers at the ISGD Clinical Trials Summit discussed new data from the FIND-CKD trial regarding the use of finerenone in patients with focal segmental glomerulosclerosis (FSGS). The study suggests that finerenone can effectively slow the decline of kidney function in patients with this rare glomerular disease.
Why it matters
This research offers potential new treatment pathways for patients with FSGS, a condition that currently has limited therapeutic options.
Hiddo Heerspink, PharmD, PhD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack finerenone’s FIND-CKD data in FSGS.
Recorded at the inaugural International Society of Glomerular Diseases (ISGD) Clinical Trials Summit in Galveston, Texas, this episode features hosts Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, with guest Hiddo Heerspink, PharmD, PhD. Heerspink is a professor of clinical trials and personalized medicine at University Medical Center Groningen.
Fresh off presenting the FIND-CKD focal segmental glomerulosclerosis (FSGS) analysis at the summit, he discusses what the data mean for a disease with few proven options and how future trials should approach treatment sequencing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in